Guidant Announces Market Release of Next Generation Pacemaker in U.S.
Indianapolis, IN, and St. Paul, MN, – March 16, 2000 – Guidant Corporation (NYSE and PCX: GDT), a worldwide leader in cardiac rhythm management systems, today announced that the FDA has approved the DISCOVERY™ II single sensor pacemaker for market release in the U.S.
"The DISCOVERY II device’s expanded diagnostic capability will complement our very successful blended sensor product, the PULSAR™ MAX pacemaker," commented Fred McCoy, president of Guidant’s Cardiac Rhythm Management Group. "DISCOVERY II was designed to greatly simplify clinician interaction with a pacemaker."
The feature addition of onset and markers, in combination with trending and arrhythmia logbook, present a therapy and arrhythmia profile that is unmatched in its comprehensiveness. Briefly, the DISCOVERY II is designed to:
Enable a physician to easily and quickly perform a comprehensive set of automatic test and follow-up operations that save time.
Provide one concise report that crisply presents information needed for informed patient management.
Guidant will begin shipping DISCOVERY II devices in early April.
A global leader in the medical device industry, Guidant provides innovative, minimally invasive and cost-effective products and services for the treatment of cardiovascular and vascular disease.